SciSparc Ltd., a specialty clinical-stage pharmaceutical company, has filed a Post-Effective Amendment No. 1 to Form F-1 with the SEC on May 2, 2024. The amendment relates to the Registration Statement on Form F-1, originally declared effective by the SEC on March 6, 2024, under Registration No. 333-277394. The filing is part of SciSparc's undertaking to update and supplement information contained in the Registration Statement concerning the offer and sale of up to 5,402,887 ordinary shares by YA II PN, LTD., a Cayman Islands exempt limited partnership managed by Yorkville Advisors Global, LP. The filing updates and supplements the Registration Statement and the prospectus contained therein, with no additional securities being registered under this amendment. The prospectus is not complete and may be changed...Show More

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, has filed a Post-Effective Amendment No. 1 to Form F-1 with the SEC on May 2, 2024. The amendment relates to the Registration Statement on Form F-1, originally declared effective by the SEC on March 6, 2024, under Registration No. 333-277394. The filing is part of SciSparc's undertaking to update and supplement information contained in the Registration Statement concerning the offer and sale of up to 5,402,887 ordinary shares by YA II PN, LTD., a Cayman Islands exempt limited partnership managed by Yorkville Advisors Global, LP. The filing updates and supplements the Registration Statement and the prospectus contained therein, with no additional securities being registered under this amendment. The prospectus is not complete and may be changed, with securities not to be sold until the amendment is effective. This prospectus relates to the offer and sale of up to 4,422,435 ordinary shares by YA II PN, LTD. The shares may be sold in various ways, including ordinary brokerage transactions, block trades, or a combination of methods. SciSparc Ltd. will not receive any proceeds from the sale of shares by the selling shareholder but may receive up to $20.0 million in aggregate gross proceeds from sales of ordinary shares to the selling shareholder under a Standby Equity Purchase Agreement (SEPA). The proceeds are intended for working capital and general corporate purposes.